新泰醫藥 MDGL 深 滬

美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价

今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元

05-08 12:05

美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价

今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元

05-07 12:37

Earnings Scheduled For May 6, 2026

Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...

05-07 05:03

Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call

On Wednesday, Madrigal Pharmaceuticals (NASDAQ:MDGL) discussed first-quarter fi...

05-06 21:23

财报速睇 | 新泰医药 2026财年Q1营收3.11亿美元，同比增长126.8%；归母净利润亏损0.94亿美元，同比亏损扩大28.9%

华盛资讯5月6日讯，新泰医药公布2026财年Q1业绩，公司Q1营收3.11亿美元，同比增长126.8%，归母净利润亏损0.94亿美元，同比亏损扩大28.9%。

05-06 21:21

HC Wainwright & Co. Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target

HC Wainwright & Co. analyst Andrew S. Fein reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and maintains $620 price target.

05-06 20:02

财报速睇 | 新泰医药 2026财年Q1营收3.11亿美元，同比增长126.7%；归母净利润亏损0.94亿美元，同比亏损扩大29.0%

华盛资讯5月6日讯，新泰医药公布2026财年Q1业绩，公司Q1营收3.11亿美元，同比增长126.7%，归母净利润亏损0.94亿美元，同比亏损扩大29.0%。

05-06 19:21

Madrigal Pharmaceuticals Announces Exclusive Global License Agreement With Arrowhead Pharmaceuticals For ARO-PNPLA3

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene, which is highly

05-05 20:02

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

05-05 12:00

Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting

The latest announcement is out from Madrigal Pharmaceuticals ( ($MDGL) ). On Ap...

04-29 05:28